CONCORD, Ohio–(Business Wire)–
Ricerca Biosciences, LLC, a uniquely integrated preclinical contract research
organization (CRO) providing services to the biopharmaceutical industry, is
pleased to announce its innovative similarity analysis service, Foresight.
Foresight allows compound assay results to be compared against the assay results
of a large reference set of pharmacologically active compounds. The tool helps
predict in vivo effects from in vitro pharmacology data and provides insight
into additional, non-obvious compound activities.
The analysis service allows scientists to discover clues to the possibilities of
a compound, providing a resource for discovery and innovation. Foresight can be
used to direct compound modification to avoid adverse effects and determine new
indications for safe or novel compounds.
“Foresight provides a glimpse into the future of a compound and uses data from
the past to suggest ways to increase the acuity of that vision. Additionally,
Foresight allows our clients to apply their scientific know-how to years of
historical data with sophisticated analysis tools. Until August 31, 2010, we are
offering an introductory price of $3,500 per compound,” stated Chairman and CEO
of Ricerca, Ian Lennox.
For over forty years, Ricerca has been working with clients to profile compounds
in the discovery space. With the development of this tool, Ricerca can now offer
interpretation and predictive analysis of pharmacological data.
Ricerca offers a unique spectrum of services for the areas of preclinical
discovery and development for biopharmaceutical registration, agrochemical
registration and environmental analysis.
About Ricerca Biosciences
Ricerca Biosciences, LLC, offers a comprehensive suite of discovery and
preclinical services to support drug candidates from discovery through IND on a
global scale. Capabilities in discovery include molecular through in vivo
screening and profiling, medicinal chemistry, IND-enabling toxicology, API
process chemistry and cGMP manufacturing and scale-up. At Ricerca, our
scientific excellence and reliable, cost-effective strategies help accelerate
your drug discovery programs via our U.S. based facilities in Concord, Ohio, and
Bothell, Washington, and our ISO 9001-certified facilities in Taipei, Taiwan,
and Lyon, France. The Lyon and Bothell facilities also hold AAALAC
Kelly Sladek, 308-237-5567
Copyright Business Wire 2010